O-6-methylguanine-DNA methyltransferase - Revision history

Jensflorian: +wikify

2018-07-09T11:30:16Z

+wikify

← Older revision		Revision as of 11:30, 9 July 2018
Line 2:		Line 2:
	Because the product can antagonize the efficiacy of alkylating substances, the methylation state of the MGMT gene determines whether tumor cells in [[glioblastoma]] would be responsive to therapy with [[temozolomide]]. A methylated (ie silenced) MGMT promotor is therefore a predictive and prognostic biomarker.<ref>{{Cite journal \| last1 = Stupp \| first1 = R. \| last2 = Hegi \| first2 = ME. \| last3 = Mason \| first3 = WP. \| last4 = van den Bent \| first4 = MJ. \| last5 = Taphoorn \| first5 = MJ. \| last6 = Janzer \| first6 = RC. \| last7 = Ludwin \| first7 = SK. \| last8 = Allgeier \| first8 = A. \| last9 = Fisher \| first9 = B. \| title = Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. \| journal = Lancet Oncol \| volume = 10 \| issue = 5 \| pages = 459-66 \| month = May \| year = 2009 \| doi = 10.1016/S1470-2045(09)70025-7 \| PMID = 19269895 }}</ref>		Because the product can antagonize the efficiacy of alkylating substances, the methylation state of the MGMT gene determines whether tumor cells in [[glioblastoma]] would be responsive to therapy with [[temozolomide]]. A methylated (ie silenced) MGMT promotor is therefore a predictive and prognostic biomarker.<ref>{{Cite journal \| last1 = Stupp \| first1 = R. \| last2 = Hegi \| first2 = ME. \| last3 = Mason \| first3 = WP. \| last4 = van den Bent \| first4 = MJ. \| last5 = Taphoorn \| first5 = MJ. \| last6 = Janzer \| first6 = RC. \| last7 = Ludwin \| first7 = SK. \| last8 = Allgeier \| first8 = A. \| last9 = Fisher \| first9 = B. \| title = Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. \| journal = Lancet Oncol \| volume = 10 \| issue = 5 \| pages = 459-66 \| month = May \| year = 2009 \| doi = 10.1016/S1470-2045(09)70025-7 \| PMID = 19269895 }}</ref>

	MGMT testing in neuropathology is usually performed by semi-quantitative methylation-specific PCR, pyrosequencing, methylation-specific multiplexed ligation probe amplification (MS-MLPA)or methylation profiling arrays. MGMT immunohistochemistry is not recommended.<ref>{{Cite journal \| last1 = Quillien \| first1 = V. \| last2 = Lavenu \| first2 = A. \| last3 = Ducray \| first3 = F. \| last4 = Joly \| first4 = MO. \| last5 = Chinot \| first5 = O. \| last6 = Fina \| first6 = F. \| last7 = Sanson \| first7 = M. \| last8 = Carpentier \| first8 = C. \| last9 = Karayan-Tapon \| first9 = L. \| title = Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial. \| journal = Oncotarget \| volume = 7 \| issue = 38 \| pages = 61916-61929 \| month = 09 \| year = 2016 \| doi = 10.18632/oncotarget.11322 \| PMID = 27542245 }}</ref><ref>{{Cite journal \| last1 = Trabelsi \| first1 = S. \| last2 = Mama \| first2 = N. \| last3 = Ladib \| first3 = M. \| last4 = Karmeni \| first4 = N. \| last5 = Haddaji Mastouri \| first5 = M. \| last6 = Chourabi \| first6 = M. \| last7 = Mokni \| first7 = M. \| last8 = Tlili \| first8 = K. \| last9 = Krifa \| first9 = H. \| title = MGMT methylation assessment in glioblastoma: MS-MLPA versus human methylation 450K beadchip array and immunohistochemistry. \| journal = Clin Transl Oncol \| volume = 18 \| issue = 4 \| pages = 391-7 \| month = Apr \| year = 2016 \| doi = 10.1007/s12094-015-1381-0 \| PMID = 26289551 }}</ref>		MGMT testing in neuropathology is usually performed by semi-quantitative methylation-specific PCR, [[pyrosequencing]], methylation-specific multiplexed ligation probe amplification (MS-MLPA)or methylation profiling arrays. MGMT immunohistochemistry is not recommended.<ref>{{Cite journal \| last1 = Quillien \| first1 = V. \| last2 = Lavenu \| first2 = A. \| last3 = Ducray \| first3 = F. \| last4 = Joly \| first4 = MO. \| last5 = Chinot \| first5 = O. \| last6 = Fina \| first6 = F. \| last7 = Sanson \| first7 = M. \| last8 = Carpentier \| first8 = C. \| last9 = Karayan-Tapon \| first9 = L. \| title = Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial. \| journal = Oncotarget \| volume = 7 \| issue = 38 \| pages = 61916-61929 \| month = 09 \| year = 2016 \| doi = 10.18632/oncotarget.11322 \| PMID = 27542245 }}</ref><ref>{{Cite journal \| last1 = Trabelsi \| first1 = S. \| last2 = Mama \| first2 = N. \| last3 = Ladib \| first3 = M. \| last4 = Karmeni \| first4 = N. \| last5 = Haddaji Mastouri \| first5 = M. \| last6 = Chourabi \| first6 = M. \| last7 = Mokni \| first7 = M. \| last8 = Tlili \| first8 = K. \| last9 = Krifa \| first9 = H. \| title = MGMT methylation assessment in glioblastoma: MS-MLPA versus human methylation 450K beadchip array and immunohistochemistry. \| journal = Clin Transl Oncol \| volume = 18 \| issue = 4 \| pages = 391-7 \| month = Apr \| year = 2016 \| doi = 10.1007/s12094-015-1381-0 \| PMID = 26289551 }}</ref>

	==See also==		==See also==

Michael at 15:05, 17 May 2017

2017-05-17T15:05:04Z

← Older revision		Revision as of 15:05, 17 May 2017
Line 1:		Line 1:
	'''O-6-methylguanine-DNA methyltransferase''' (MGMT) is a gene encoding for O6-alkylguanine DNA alkyltransferase which is required for genomic stability.		'''O-6-methylguanine-DNA methyltransferase''', abbreviated '''MGMT''', is a gene encoding for O6-alkylguanine DNA alkyltransferase which is required for genomic stability.
	Because the product can antagonize the efficiacy of alkylating substances, the methylation state of the MGMT gene determines whether tumor cells in [[glioblastoma]] would be responsive to therapy with [[temozolomide]]. A methylated (ie silenced) MGMT promotor is therefore a predictive and prognostic biomarker.<ref>{{Cite journal \| last1 = Stupp \| first1 = R. \| last2 = Hegi \| first2 = ME. \| last3 = Mason \| first3 = WP. \| last4 = van den Bent \| first4 = MJ. \| last5 = Taphoorn \| first5 = MJ. \| last6 = Janzer \| first6 = RC. \| last7 = Ludwin \| first7 = SK. \| last8 = Allgeier \| first8 = A. \| last9 = Fisher \| first9 = B. \| title = Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. \| journal = Lancet Oncol \| volume = 10 \| issue = 5 \| pages = 459-66 \| month = May \| year = 2009 \| doi = 10.1016/S1470-2045(09)70025-7 \| PMID = 19269895 }}</ref>		Because the product can antagonize the efficiacy of alkylating substances, the methylation state of the MGMT gene determines whether tumor cells in [[glioblastoma]] would be responsive to therapy with [[temozolomide]]. A methylated (ie silenced) MGMT promotor is therefore a predictive and prognostic biomarker.<ref>{{Cite journal \| last1 = Stupp \| first1 = R. \| last2 = Hegi \| first2 = ME. \| last3 = Mason \| first3 = WP. \| last4 = van den Bent \| first4 = MJ. \| last5 = Taphoorn \| first5 = MJ. \| last6 = Janzer \| first6 = RC. \| last7 = Ludwin \| first7 = SK. \| last8 = Allgeier \| first8 = A. \| last9 = Fisher \| first9 = B. \| title = Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. \| journal = Lancet Oncol \| volume = 10 \| issue = 5 \| pages = 459-66 \| month = May \| year = 2009 \| doi = 10.1016/S1470-2045(09)70025-7 \| PMID = 19269895 }}</ref>

Michael at 15:04, 17 May 2017

2017-05-17T15:04:23Z

← Older revision		Revision as of 15:04, 17 May 2017
Line 4:		Line 4:
	MGMT testing in neuropathology is usually performed by semi-quantitative methylation-specific PCR, pyrosequencing, methylation-specific multiplexed ligation probe amplification (MS-MLPA)or methylation profiling arrays. MGMT immunohistochemistry is not recommended.<ref>{{Cite journal \| last1 = Quillien \| first1 = V. \| last2 = Lavenu \| first2 = A. \| last3 = Ducray \| first3 = F. \| last4 = Joly \| first4 = MO. \| last5 = Chinot \| first5 = O. \| last6 = Fina \| first6 = F. \| last7 = Sanson \| first7 = M. \| last8 = Carpentier \| first8 = C. \| last9 = Karayan-Tapon \| first9 = L. \| title = Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial. \| journal = Oncotarget \| volume = 7 \| issue = 38 \| pages = 61916-61929 \| month = 09 \| year = 2016 \| doi = 10.18632/oncotarget.11322 \| PMID = 27542245 }}</ref><ref>{{Cite journal \| last1 = Trabelsi \| first1 = S. \| last2 = Mama \| first2 = N. \| last3 = Ladib \| first3 = M. \| last4 = Karmeni \| first4 = N. \| last5 = Haddaji Mastouri \| first5 = M. \| last6 = Chourabi \| first6 = M. \| last7 = Mokni \| first7 = M. \| last8 = Tlili \| first8 = K. \| last9 = Krifa \| first9 = H. \| title = MGMT methylation assessment in glioblastoma: MS-MLPA versus human methylation 450K beadchip array and immunohistochemistry. \| journal = Clin Transl Oncol \| volume = 18 \| issue = 4 \| pages = 391-7 \| month = Apr \| year = 2016 \| doi = 10.1007/s12094-015-1381-0 \| PMID = 26289551 }}</ref>		MGMT testing in neuropathology is usually performed by semi-quantitative methylation-specific PCR, pyrosequencing, methylation-specific multiplexed ligation probe amplification (MS-MLPA)or methylation profiling arrays. MGMT immunohistochemistry is not recommended.<ref>{{Cite journal \| last1 = Quillien \| first1 = V. \| last2 = Lavenu \| first2 = A. \| last3 = Ducray \| first3 = F. \| last4 = Joly \| first4 = MO. \| last5 = Chinot \| first5 = O. \| last6 = Fina \| first6 = F. \| last7 = Sanson \| first7 = M. \| last8 = Carpentier \| first8 = C. \| last9 = Karayan-Tapon \| first9 = L. \| title = Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial. \| journal = Oncotarget \| volume = 7 \| issue = 38 \| pages = 61916-61929 \| month = 09 \| year = 2016 \| doi = 10.18632/oncotarget.11322 \| PMID = 27542245 }}</ref><ref>{{Cite journal \| last1 = Trabelsi \| first1 = S. \| last2 = Mama \| first2 = N. \| last3 = Ladib \| first3 = M. \| last4 = Karmeni \| first4 = N. \| last5 = Haddaji Mastouri \| first5 = M. \| last6 = Chourabi \| first6 = M. \| last7 = Mokni \| first7 = M. \| last8 = Tlili \| first8 = K. \| last9 = Krifa \| first9 = H. \| title = MGMT methylation assessment in glioblastoma: MS-MLPA versus human methylation 450K beadchip array and immunohistochemistry. \| journal = Clin Transl Oncol \| volume = 18 \| issue = 4 \| pages = 391-7 \| month = Apr \| year = 2016 \| doi = 10.1007/s12094-015-1381-0 \| PMID = 26289551 }}</ref>

			==See also==
			*[[Neuropathology]].
			*[[Temozolomide]].

			==References==
			{{Reflist\|1}}

	[[Category:Neuropathology]]		[[Category:Neuropathology]]

Jensflorian: created

2017-03-23T11:21:02Z

created

New page

'''O-6-methylguanine-DNA methyltransferase''' (MGMT) is a gene encoding for O6-alkylguanine DNA alkyltransferase which is required for genomic stability.
Because the product can antagonize the efficiacy of alkylating substances, the methylation state of the MGMT gene determines whether tumor cells in [[glioblastoma]] would be responsive to therapy with [[temozolomide]]. A methylated (ie silenced) MGMT promotor is therefore a predictive and prognostic biomarker.<ref>{{Cite journal | last1 = Stupp | first1 = R. | last2 = Hegi | first2 = ME. | last3 = Mason | first3 = WP. | last4 = van den Bent | first4 = MJ. | last5 = Taphoorn | first5 = MJ. | last6 = Janzer | first6 = RC. | last7 = Ludwin | first7 = SK. | last8 = Allgeier | first8 = A. | last9 = Fisher | first9 = B. | title = Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. | journal = Lancet Oncol | volume = 10 | issue = 5 | pages = 459-66 | month = May | year = 2009 | doi = 10.1016/S1470-2045(09)70025-7 | PMID = 19269895 }}</ref>

MGMT testing in neuropathology is usually performed by semi-quantitative methylation-specific PCR, pyrosequencing, methylation-specific multiplexed ligation probe amplification (MS-MLPA)or methylation profiling arrays. MGMT immunohistochemistry is not recommended.<ref>{{Cite journal | last1 = Quillien | first1 = V. | last2 = Lavenu | first2 = A. | last3 = Ducray | first3 = F. | last4 = Joly | first4 = MO. | last5 = Chinot | first5 = O. | last6 = Fina | first6 = F. | last7 = Sanson | first7 = M. | last8 = Carpentier | first8 = C. | last9 = Karayan-Tapon | first9 = L. | title = Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial. | journal = Oncotarget | volume = 7 | issue = 38 | pages = 61916-61929 | month = 09 | year = 2016 | doi = 10.18632/oncotarget.11322 | PMID = 27542245 }}</ref><ref>{{Cite journal | last1 = Trabelsi | first1 = S. | last2 = Mama | first2 = N. | last3 = Ladib | first3 = M. | last4 = Karmeni | first4 = N. | last5 = Haddaji Mastouri | first5 = M. | last6 = Chourabi | first6 = M. | last7 = Mokni | first7 = M. | last8 = Tlili | first8 = K. | last9 = Krifa | first9 = H. | title = MGMT methylation assessment in glioblastoma: MS-MLPA versus human methylation 450K beadchip array and immunohistochemistry. | journal = Clin Transl Oncol | volume = 18 | issue = 4 | pages = 391-7 | month = Apr | year = 2016 | doi = 10.1007/s12094-015-1381-0 | PMID = 26289551 }}</ref>

[[Category:Neuropathology]]